New Zealand markets open in 6 hours 12 minutes

Intra-Cellular Therapies, Inc. (ITCI)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
65.54-0.83 (-1.25%)
At close: 04:00PM EDT
65.55 +0.01 (+0.02%)
After hours: 04:09PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 6.92B
Enterprise value 6.46B
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)12.32
Price/book (mrq)11.54
Enterprise value/revenue 12.61
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 1.00
52-week change 310.28%
S&P500 52-week change 326.14%
52-week high 384.89
52-week low 345.50
50-day moving average 368.80
200-day moving average 362.96

Share statistics

Avg vol (3-month) 3945.72k
Avg vol (10-day) 3796.33k
Shares outstanding 5105.58M
Implied shares outstanding 6105.58M
Float 8103.36M
% held by insiders 12.32%
% held by institutions 189.60%
Shares short (30 Apr 2024) 43.67M
Short ratio (30 Apr 2024) 42.78
Short % of float (30 Apr 2024) 43.99%
Short % of shares outstanding (30 Apr 2024) 43.48%
Shares short (prior month 28 Mar 2024) 43.47M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin -21.57%
Operating margin (ttm)-14.46%

Management effectiveness

Return on assets (ttm)-11.23%
Return on equity (ttm)-18.07%

Income statement

Revenue (ttm)513.93M
Revenue per share (ttm)5.34
Quarterly revenue growth (yoy)52.00%
Gross profit (ttm)N/A
EBITDA -131.41M
Net income avi to common (ttm)-110.87M
Diluted EPS (ttm)-1.16
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)475.62M
Total cash per share (mrq)4.51
Total debt (mrq)16.38M
Total debt/equity (mrq)2.73%
Current ratio (mrq)5.12
Book value per share (mrq)6.15

Cash flow statement

Operating cash flow (ttm)-98.25M
Levered free cash flow (ttm)-18.29M